Common Cold

11
Pipeline Programs
5
Companies
7
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
4
5
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

U
DELSYMApproved
dextromethorphan
Unknown Company
Uncompetitive N-methyl-D-aspartate Receptor Antagonist [EPC]oral1982
U
MUCOSIL-10Approved
acetylcysteine
Unknown Company
inhalation, oral1986
U
MUCOSIL-20Approved
acetylcysteine
Unknown Company
inhalation, oral1986

Competitive Landscape

5 companies ranked by most advanced pipeline stage

GSK
GSKLONDON, United Kingdom
5 programs
1
1
2
1
Paracetamol and CaffeinePhase 41 trial
AcetylcystinePhase 31 trial
paracetamol + caffeinePhase 31 trial
Paracetamol hot drinkPhase 21 trial
Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mgPhase 11 trial
Active Trials
NCT03415243Completed28Est. Mar 2018
NCT01277081Completed200Est. Dec 2010
NCT02822287Completed58Est. Mar 2016
+2 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
DextromethorphanPhase 4
Sandoz
SandozAustria - Kundl
1 program
1
AcetylcysteinePhase 3
Novartis
NovartisBASEL, Switzerland
1 program
1
XylometazolinePhase 31 trial
Active Trials
NCT00452270Completed60Est. Apr 2007
Marinomed Biotech
Marinomed BiotechAustria - Korneuburg
1 program
Coldamaris lozengesN/A1 trial
Active Trials
NCT04533906Completed29Est. Nov 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKParacetamol and Caffeine
GSKAcetylcystine
GSKparacetamol + caffeine
NovartisXylometazoline
GSKParacetamol hot drink
GSKAcetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg
Marinomed BiotechColdamaris lozenges

Clinical Trials (7)

Total enrollment: 687 patients across 7 trials

NCT01466348GSKParacetamol and Caffeine

Effects of a Common Cold Treatment on Cognitive Function

Start: Feb 2011Est. completion: Apr 201172 patients
Phase 4Completed
NCT02822287GSKAcetylcystine

Warming Sensation and Tolerability Study of Acetylcysteine 2% Oral Solution for Productive Cough

Start: Feb 2016Est. completion: Mar 201658 patients
Phase 3Completed
NCT01686646GSKparacetamol + caffeine

Effects of Two Doses of a Common Cold Treatment on Alertness

Start: Nov 2011Est. completion: Nov 2012240 patients
Phase 3Completed
NCT00452270NovartisXylometazoline

Decongestant Effect, Timing of Effect and Impact on Sleep and General Well-Being of Xylometazoline in Subjects With a Common Cold

Start: Mar 2007Est. completion: Apr 200760 patients
Phase 3Completed
NCT01277081GSKParacetamol hot drink

Effect of Paracetamol on the Common Cold

Start: Oct 2010Est. completion: Dec 2010200 patients
Phase 2Completed
NCT03415243GSKAcetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg

To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers

Start: Mar 2018Est. completion: Mar 201828 patients
Phase 1Completed
NCT04533906Marinomed BiotechColdamaris lozenges

Study to Investigate if Sucking a Coldamaris Lozenge Elutes Sufficient Iota-carrageenan to Inactivate Usual Common Cold Viruses

Start: Aug 2020Est. completion: Nov 202029 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
5 companies competing in this space